PUBLISHER: The Business Research Company | PRODUCT CODE: 1945283
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945283
The hemoglobin A1c testing device serves as the analytical tool utilized in quantifying HbA1C. In this process, glucose binds to hemoglobin, forming glycated hemoglobin within an individual's blood sample. Its purpose is to monitor blood sugar levels consistently, contributing to efficient and effective diabetic management.
Two primary types of hemoglobin A1c testing devices exist, benchtop devices and handheld devices. Benchtop devices are designed for convenient usage on a laboratory workbench. Employed in laboratories to assess blood sugar levels in patients, benchtop hemoglobin A1c testing devices make use of various technologies such as ion exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay, and others. These technologies find application in hospitals, pharmaceuticals, medical devices, and laboratory testing.
Tariffs are influencing the hemoglobin a1c testing devices market by increasing costs of imported sensors, reagents, electronic components, and precision analyzers. Hospitals and laboratories in North America and Europe are most affected due to reliance on imported diagnostic equipment, while Asia-Pacific faces higher production costs for export devices. These tariffs are increasing testing device prices and slowing procurement cycles. However, they are also promoting domestic manufacturing, local reagent production, and development of cost-effective point-of-care testing solutions.
The hemoglobin a1c testing devices market research report is one of a series of new reports from The Business Research Company that provides hemoglobin a1c testing devices market statistics, including hemoglobin a1c testing devices industry global market size, regional shares, competitors with a hemoglobin a1c testing devices market share, detailed hemoglobin a1c testing devices market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobin a1c testing devices industry. This hemoglobin a1c testing devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hemoglobin a1c testing devices market size has grown rapidly in recent years. It will grow from $2.08 billion in 2025 to $2.32 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising prevalence of diabetes, expansion of routine blood glucose monitoring practices, improved availability of laboratory diagnostics, growing awareness of glycemic control, adoption of standardized diabetes testing protocols.
The hemoglobin a1c testing devices market size is expected to see rapid growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing demand for home-based diabetes monitoring, rising integration of ai-driven analytics, expansion of remote patient monitoring, growing focus on personalized diabetes care, increasing adoption of smart diagnostic devices. Major trends in the forecast period include increasing adoption of point-of-care hba1c testing, rising use of portable and handheld devices, growing integration with digital diabetes management platforms, expansion of rapid and high-accuracy assays, enhanced focus on patient-centric monitoring.
The increasing prevalence of diabetes is anticipated to accelerate the growth of the hemoglobin A1c testing devices market. Diabetes is a long-term metabolic condition characterized by elevated blood glucose levels. Hemoglobin A1c testing provides insights into an individual's average blood glucose levels over time and is widely used for the diagnosis of type 2 diabetes, identification of pre-diabetes, and ongoing diabetes management. This testing supports effective disease monitoring and informed treatment decisions, helping to reduce the risk of complications. For example, in June 2024, data from the National Health Service, a United Kingdom-based government department, indicated that in 2023 more than half a million additional individuals in England (549,000) were identified as being at risk of developing type 2 diabetes. This increased the total number of people registered with general practitioners as having non-diabetic hyperglycemia, or pre-diabetes, to 3,615,330, compared with 3,065,825 in 2022, representing an increase of nearly 20%. As a result, the growing number of diabetes cases is expected to drive demand for hemoglobin A1c testing devices.
Leading companies in the hemoglobin A1c testing devices market are prioritizing the development of innovative offerings, including at-home or micro-sample HbA1c collection kits, to address rising demand driven by increasing diabetes prevalence, the expansion of decentralized care and telehealth models, and patient preferences for convenient and cost-effective monitoring solutions. An at-home HbA1c collection kit is a user-friendly solution that allows individuals to collect a small finger-prick blood sample, typically just a few drops, stabilize the sample for transport, and send it to a certified laboratory for accurate analysis. For instance, in February 2023, Hurdle, a United States-based diagnostics-as-a-service company, introduced a Hemoglobin A1c (HbA1c) Test through its Chronomics direct-to-consumer platform. The offering includes a home sample collection kit with finger-prick lancets and a sample card or tube, secure online registration via a personal dashboard, and courier return to partner Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. The service delivers laboratory-grade analysis with an average turnaround time of approximately three days after receipt, along with integrated result interpretation and optional one-to-one access to healthcare professionals, combining the convenience of home sampling with the accuracy and consistency of centralized laboratory testing.
In October 2023, Abbott Laboratories, a U.S.-based medical device company, entered into a partnership with WW International. This collaboration integrates Abbott's FreeStyle Libre continuous glucose monitoring technology with WeightWatchers' diabetes-focused weight management program, offering real-time glucose insights and personalized nutritional guidance to help individuals with diabetes make informed dietary choices and improve both weight management and glycemic control. WW International, Inc. is a U.S.-based company that provides services for weight loss and maintenance, fitness, and mindset, including the comprehensive Weight Watchers diet program.
Major companies operating in the hemoglobin a1c testing devices market are Arkray Inc, Abbott Laboratories, Polymer Technology Systems Inc, Bio-Rad Laboratories Inc, Menarini Group, F Hoffmann-La Roche AG, Siemens Healthineers AG, Tosoh Corporation, Trinity Biotech plc, Transasia Bio-Medicals Limited, Beckman Coulter Inc, Diazyme Laboratories Inc, EKF Diagnostics Holdings plc, HemoCue AB, OSANG Healthcare Co Ltd, Danaher, Thermo Fisher Scientific Inc., PTS Diagnostics India Private Limited, Nova Biomedical, Randox Laboratories Ltd., ACON Laboratories Inc., DiaSys Diagnostic Systems GmbH, Erba Mannheim, Green Cross Medical Science Corp., Infopia Co. Ltd., TaiDoc Technology Corporation, Werfen, Zhejiang Orient Gene Biotech Co. Ltd.
North America was the largest region in the hemoglobin A1C testing devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hemoglobin A1C testing devices market during the forecast period. The regions covered in the hemoglobin a1c testing devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the hemoglobin a1c testing devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The hemoglobin A1c testing device market consists of sales of automated, semi-automated, and bio-sensor-based hemoglobin A1c testing devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hemoglobin A1c Testing Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses hemoglobin a1c testing devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hemoglobin a1c testing devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemoglobin a1c testing devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.